Traders Purchase High Volume of Forte Biosciences Call Options (NASDAQ:FBRX)

Forte Biosciences, Inc. (NASDAQ:FBRXGet Rating) was the target of unusually large options trading activity on Wednesday. Stock investors acquired 30,205 call options on the company. This is an increase of 1,663% compared to the typical volume of 1,713 call options.

Shares of FBRX opened at $1.12 on Thursday. The firm has a 50 day simple moving average of $1.36 and a 200-day simple moving average of $1.82. Forte Biosciences has a 1-year low of $1.03 and a 1-year high of $7.26.

Forte Biosciences (NASDAQ:FBRXGet Rating) last issued its quarterly earnings data on Monday, May 16th. The company reported ($0.17) earnings per share for the quarter. As a group, sell-side analysts expect that Forte Biosciences will post -0.77 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in FBRX. GSA Capital Partners LLP acquired a new position in shares of Forte Biosciences in the 3rd quarter valued at $152,000. Aries Wealth Management purchased a new position in shares of Forte Biosciences in the 4th quarter valued at $195,000. Jump Financial LLC purchased a new position in shares of Forte Biosciences in the 3rd quarter valued at $35,000. Centiva Capital LP purchased a new position in shares of Forte Biosciences in the 3rd quarter valued at $31,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Forte Biosciences in the 3rd quarter valued at $68,000. Hedge funds and other institutional investors own 37.11% of the company’s stock.

Forte Biosciences Company Profile (Get Rating)

Forte Biosciences, Inc operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Featured Stories

Receive News & Ratings for Forte Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forte Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.